Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Free Report) was the recipient of a significant decline in short interest in September. As of September 15th, there was short interest totaling 13,076 shares, a decline of 36.6% from the August 31st total of 20,626 shares. Based on an average trading volume of 1,979 shares, the days-to-cover ratio is currently 6.6 days.
Algernon Pharmaceuticals Trading Down 2.6%
Shares of OTCMKTS AGNPF opened at $0.28 on Thursday. Algernon Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $0.64. The company has a 50-day moving average price of $0.33 and a 200-day moving average price of $0.26.
Algernon Pharmaceuticals Company Profile
Algernon Pharmaceuticals Inc is a Canadian clinical-stage pharmaceutical development company focused on discovering and advancing therapeutics for diseases with significant unmet medical needs. The company has primarily pursued a drug-repurposing strategy, evaluating existing compounds for potential applications in respiratory, neurological and other serious conditions.
Algernon’s development programs have included NP-120, an extended-release formulation of ifenprodil. The company has investigated ifenprodil as a potential treatment for conditions including idiopathic pulmonary fibrosis, chronic cough and ischemic stroke, and has also evaluated the compound in connection with respiratory disease research.
See Also
- Five stocks we like better than Algernon Pharmaceuticals
- Anthropic’s IPO Could Put Amazon’s and Alphabet’s Paper Profits to the Test
- Microsoft’s AI Spending Didn’t Change—Wall Street’s View of It Did
- Cleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach
- L3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock
Receive News & Ratings for Algernon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Algernon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
